These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36825053)

  • 1. A Pilot Trial of Dopamine Replacement for Dynamic Facial Expressions in Parkinson's Disease.
    Schade RN; Springer U; Mikos A; Gokcay D; Clark A; Sapienza C; Fernandez HH; Okun MS; Bowers D
    Mov Disord Clin Pract; 2023 Feb; 10(2):213-222. PubMed ID: 36825053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Faces of emotion in Parkinsons disease: micro-expressivity and bradykinesia during voluntary facial expressions.
    Bowers D; Miller K; Bosch W; Gokcay D; Pedraza O; Springer U; Okun M
    J Int Neuropsychol Soc; 2006 Nov; 12(6):765-73. PubMed ID: 17064440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laterality of motor symptom onset and facial expressivity in Parkinson disease using face digitization.
    Ratajska AM; Nisenzon AN; Lopez FV; Clark AL; Gokcay D; Okun MS; Bowers D
    Laterality; 2022 Jan; 27(1):57-70. PubMed ID: 34225573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.
    Markham A; Benfield P
    CNS Drugs; 1997 Apr; 7(4):328-40. PubMed ID: 27520755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired recognition of facial expressions of anger in Parkinson's disease patients acutely withdrawn from dopamine replacement therapy.
    Lawrence AD; Goerendt IK; Brooks DJ
    Neuropsychologia; 2007 Jan; 45(1):65-74. PubMed ID: 16780901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different effects of levodopa and subthalamic stimulation on emotional conflict in Parkinson's disease.
    Martínez-Fernández R; Kibleur A; Chabardès S; Fraix V; Castrioto A; Lhommée E; Moro E; Lescoules L; Pelissier P; David O; Krack P
    Hum Brain Mapp; 2018 Dec; 39(12):5014-5027. PubMed ID: 30259598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Jaw movement dysfunction related to Parkinson's disease and partially modified by levodopa.
    Robertson LT; Hammerstad JP
    J Neurol Neurosurg Psychiatry; 1996 Jan; 60(1):41-50. PubMed ID: 8558149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
    Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
    CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facial Emotion Recognition and Expression in Parkinson's Disease: An Emotional Mirror Mechanism?
    Ricciardi L; Visco-Comandini F; Erro R; Morgante F; Bologna M; Fasano A; Ricciardi D; Edwards MJ; Kilner J
    PLoS One; 2017; 12(1):e0169110. PubMed ID: 28068393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of levodopa on corticostriatal circuits supporting working memory in Parkinson's disease.
    Simioni AC; Dagher A; Fellows LK
    Cortex; 2017 Aug; 93():193-205. PubMed ID: 28675834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease.
    Espay AJ; Giuffrida JP; Chen R; Payne M; Mazzella F; Dunn E; Vaughan JE; Duker AP; Sahay A; Kim SJ; Revilla FJ; Heldman DA
    Mov Disord; 2011 Dec; 26(14):2504-8. PubMed ID: 21953789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabergoline for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; 2001(1):CD001518. PubMed ID: 11279720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Parkinson's disease and levodopa on functional limits of stability.
    Mancini M; Rocchi L; Horak FB; Chiari L
    Clin Biomech (Bristol, Avon); 2008 May; 23(4):450-8. PubMed ID: 18155331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic therapy promotes lateralized motor activity in the subthalamic area in Parkinson's disease.
    Androulidakis AG; Kühn AA; Chen CC; Blomstedt P; Kempf F; Kupsch A; Schneider GH; Doyle L; Dowsey-Limousin P; Hariz MI; Brown P
    Brain; 2007 Feb; 130(Pt 2):457-68. PubMed ID: 17213215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001516. PubMed ID: 11279718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.
    Antonini A; Odin P; Pahwa R; Aldred J; Alobaidi A; Jalundhwala YJ; Kukreja P; Bergmann L; Inguva S; Bao Y; Chaudhuri KR
    Adv Ther; 2021 Jun; 38(6):2854-2890. PubMed ID: 34018146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease.
    Gencler OS; Oztekin N; Oztekin MF
    Ideggyogy Sz; 2022 Jan; 75(1-02):39-49. PubMed ID: 35112520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-band oscillations in the supplementary motor cortex are modulated by levodopa and associated with functional activity in the basal ganglia.
    Chung JW; Burciu RG; Ofori E; Coombes SA; Christou EA; Okun MS; Hess CW; Vaillancourt DE
    Neuroimage Clin; 2018; 19():559-571. PubMed ID: 29984164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.
    Espay AJ; Stocchi F; Pahwa R; Albanese A; Ellenbogen A; Ferreira JJ; Giladi N; Gurevich T; Hassin-Baer S; Hernandez-Vara J; Isaacson SH; Kieburtz K; LeWitt PA; Lopez-Manzanares L; Olanow CW; Poewe W; Sarva H; Yardeni T; Adar L; Salin L; Lopes N; Sasson N; Case R; Rascol O;
    Lancet Neurol; 2024 May; 23(5):465-476. PubMed ID: 38499015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.